Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
Open Access
- 1 January 2015
- journal article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. 7, 47-50
Abstract
This is a unique report of two cases of patients with end-stage renal disease on hemodialysis, receiving ipilimumab for treatment of metastatic melanoma, as there is a paucity of safety and efficacy data in this patient subgroup.Keywords
This publication has 8 references indexed in Scilit:
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Ipilimumab-induced immune-related renal failure--a case report.2012
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012European Journal of Cancer, 2012
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic MelanomaClinical Cancer Research, 2012
- The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human UseEuropean Journal of Cancer, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Anti-CTLA4 Antibody–Induced Lupus NephritisNew England Journal of Medicine, 2009